Ascletis Pharma’s $400 Million Initial Public Offering

Paul Hastings advised Morgan Stanley, Goldman Sachs and China Merchant Securities as the joint sponsors in Ascletis Pharma’s US$400 million global offering and Hong Kong IPO, which is the first biotechnology company listing on the Main Board of the Hong Kong Stock Exchange under Chapter 18A, the new chapter of the Listing Rules effective since April 2018 designed to attract early-stage biotech companies.

The Paul Hastings team provided innovative legal advice and worked efficiently on the transaction that was completed in less than five months since the formal kick-off.

Ascletis Pharma is a Chinese biotechnology company focusing on developing and commercializing innovative best-in-class drugs against Hepatitis B, Hepatitis C and HIV, and has a robust R&D pipeline with multiple breakthrough drug candidates.

The Paul Hastings team was led by capital markets partners Nan Li (Picture) and Steven Winegar, with support from associates Crystal Zhang, Ke Zhang, Erika Zhao and Berton Wang.

Involved fees earner: Nan Li – Paul Hastings; Steven Winegar – Paul Hastings; Crystal Zhang – Paul Hastings; Ke Zhang – Paul Hastings; Erika Zhao – Paul Hastings; Berton Wang – Paul Hastings;

Law Firms: Paul Hastings;

Clients: Goldman, Sachs & Co.; Morgan Stanley; China Merchants Securities ;


Author: Michael Patrini